Vision, Integrity, Expertise
Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Thursday, August 27, 2015Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS
Wednesday, August 19, 2015Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
Wednesday, August 12, 2015Soligenix Announces Recent Highlights and Second Quarter 2015 Financial Results
Sunday, August 2, 2015 - Soligenix Aims to Improve Quality of Life for Patients with Cutaneous Lymphoma (lymphomainfo.net)
Friday, July 17, 2015 - International Innovation - Bullseye: Targeting Cancer with Selective Innovations, Issue 190 (pdf)
Partnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.